Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.

  • Authors:
    • A Watanuki
    • S Ohwada
    • T Fukusato
    • S Kawate
    • F Makita
    • Y Morishita
  • View Affiliations

  • Published online on: November 1, 1998     https://doi.org/10.3892/ijo.13.5.1017
  • Pages: 1017-1039
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been reported that hepatitis C virus-related hepatocellular carcinoma (HCC) patients survive longer than hepatitis B virus-related patients. In this study, since HCC patients positive for anti-HCV antibody had significantly longer disease-free survival (p<0.05), we evaluated the proliferative activity of 58 resected HCCs and the status of their viral infections. Ki-67 (MIB-1) immunostaining, argyrophilic nucleolar organizer regions and c-myc gene amplification were examined as parameters of proliferation, and p53 overexpression was examined in relation to clinicopathologic features and prognosis. Thirty-nine patients with HCC (67%) were positive for anti-HCV antibody alone, five (9%) were negative for both anti-HCV and HBV antibodies, two (3%) were positive for both anti-HCV and HBV antibodies, and 12 (21%) had HBsAg alone. HCC patients with anti-HCV antibody had a lower MIB-1 labeling index (LI) than HCC patients negative for the antibody (p<0.05), irrespective of the serum HBsAg status. However, there was no significant correlation between anti-HCV antibody and other proliferative parameters. MIB-1 could simply be related to cellular proliferation. On the other hand, the other parameters may be related to tumor progression as well as proliferation. HCV-related HCC does have lower proliferative activity and a better prognosis.

Related Articles

Journal Cover

Nov 1998
Volume 13 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Watanuki A, Ohwada S, Fukusato T, Kawate S, Makita F and Morishita Y: Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.. Int J Oncol 13: 1017-1039, 1998
APA
Watanuki, A., Ohwada, S., Fukusato, T., Kawate, S., Makita, F., & Morishita, Y. (1998). Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.. International Journal of Oncology, 13, 1017-1039. https://doi.org/10.3892/ijo.13.5.1017
MLA
Watanuki, A., Ohwada, S., Fukusato, T., Kawate, S., Makita, F., Morishita, Y."Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.". International Journal of Oncology 13.5 (1998): 1017-1039.
Chicago
Watanuki, A., Ohwada, S., Fukusato, T., Kawate, S., Makita, F., Morishita, Y."Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.". International Journal of Oncology 13, no. 5 (1998): 1017-1039. https://doi.org/10.3892/ijo.13.5.1017